| Market cap | $477.21M |
|---|---|
| Enterprise value | $861.21M |
| Revenue | $2.821B |
|---|---|
| EBITDA | $97.894M |
| Income | -$64.30 |
| Revenue Q/Q | -17.84% |
| Revenue Y/Y | -13.43% |
| P/E | N/A |
|---|---|
| Forward P/E | 5.97 |
| EV/Sales | 0.31 |
| EV/EBITDA | 8.80 |
| EV/EBIT | N/A |
| PEG | N/A |
| Price/Sales | 0.17 |
| P/FCF | N/A |
| Price/Book | 0.53 |
| Book/Share | 28.28 |
| Cash/Share | 0.19 |
| FCF yield | -7.86% |
| Volume | 386.316k / N/A |
|---|---|
| Relative vol. | N/A |
| EPS | N/A |
|---|---|
| EPS Q/Q | 14.71% |
| Est. EPS Q/Q | -108.57% |
| Profit margin | -0.89% |
|---|---|
| Oper. margin | -1.76% |
| Gross margin | 10.68% |
| EBIT margin | -1.72% |
| EBITDA margin | 3.47% |
| Ret. on assets | -3.66% |
|---|---|
| Ret. on equity | -7.21% |
| ROIC | -0.56% |
| ROCE | -3.36% |
| Debt/Equity | 0.89 |
|---|---|
| Net debt/EBITDA | 17.33 |
| Current ratio | 1.96 |
| Quick ratio | 0.92 |
| Volatility | 4.59% |
|---|---|
| Beta | 1.39 |
| RSI | 29.60 |
|---|
| Insider ownership | N/A |
|---|---|
| Inst. ownership | N/A |
| Shares outst. | 27.782M |
|---|---|
| Shares float | 0.000 0.00% |
| Short % of float | 11.19% |
| Short ratio | 1.58 |
| Dividend | $0.75 |
|---|---|
| Dividend yield | 4.89% |
| Payout ratio | 197.89% |
| Payment date | N/A |
| Ex-dividend date | N/A |
| Earnings date | 25 Jun 2024 |
Thursday, 11 August 2022
|
|
| Menarini Group's Elacestrant Granted Priority Review by the U.S. FDA for Patients with ER+/HER2- Advanced or Metastatic Breast Cancer | |
Friday, 15 July 2022
|
|
| Dave & Busters Entertainment and USA Truck Stock See Action From Activist Investors | |
Friday, 24 June 2022
|
|
| Velan-Repertoire Comments on Proposed Sale of Radius Health to Gurnet Point Capital and Patient Square Capital | |
Tuesday, 21 June 2022
|
|
| Velan-Repertoire Releases Detailed Presentation on the Need for Board Change at Radius Health and Sends Letter to Stockholders - Yahoo Finance | |
Thursday, 24 February 2022
|
|
| Radius Health Q4 2021 Earnings Call Transcript | |
Wednesday, 17 November 2021
|
|
| These 40 Mass. firms made the new Deloitte Fast 500 list | |
Monday, 8 November 2021
|
|
| Radius Health Q3 2021 Earnings Call Transcript | |
Friday, 7 May 2021
|
|
| Radius Health Reports Q1 Loss, Lags Revenue Estimates | |
Saturday, 27 March 2021
|
|
| Radius Health Up 14.7% Since Last Earnings Report: Can It Continue? | |
Friday, 26 February 2021
|
|
| Radius' Q4 Loss Wider Than Expected, Revenues Beat | |
Thursday, 25 February 2021
|
|
| Radius Health Q4 2020 Earnings Call Transcript | |
Monday, 25 January 2021
|
|
| Aurinia Gets FDA Nod for Kidney Disorder Drug Lupkynis | |
Thursday, 7 January 2021
|
|
| Radius to Acquire Rights for Cannabidiol Oral Solution | |
Friday, 18 December 2020
|
|
| Is RDUS A Good Stock To Buy According To Hedge Funds? | |
Saturday, 5 December 2020
|
|
| Radius Health Up 3.7% Since Last Earnings Report: Can It Continue? | |
Monday, 10 August 2020
|
|
| Radius Health Q2 2020 Earnings Call Transcript | |
Friday, 17 July 2020
|
|
| Did Hedge Funds Make The Right Call On Radius Health Inc ? | |
Tuesday, 16 June 2020
|
|
| Do Hedge Funds Love Radius Health Inc ? | |
Wednesday, 10 June 2020
|
|
| Edited Transcript of RDUS earnings conference call or presentation 7-May-20 8:45pm GMT | |
Friday, 8 May 2020
|
|
| Radius' Q1 Earnings Miss Estimates, Sales Surpass | |
Monday, 2 March 2020
|
|
| Radius Q4 Earnings Beat Estimates on Tymlos Strength | |
Tuesday, 25 February 2020
|
|
| Does Radius Health, Inc. Have A Volatile Share Price? | |
Thursday, 20 February 2020
|
|
| Earnings Preview: Radius Health Q4 Earnings Expected to Decline | |
| Insider |
Trans.
Transaction
|
Total value |
|---|---|---|
| Stefano R. Gaggini SVP and CFO | Sale 6 May 2024 | $18,960 |
| Brian Souza SVP and Chief Ops Mgmt Officer | Sale 10 Nov 2023 | $105,705 |
| Steven Heiskell SVP, President, Recycling P, and S | Sale 7 Nov 2023 | $193,120 |
| James Matthew Vaughn SVP, GC, CCO, and Corp. Secretary | Sale 6 Nov 2023 | $14,178 |
| Stefano R. Gaggini SVP and CFO | Sale 3 Nov 2023 | $180,707 |
| Capital Management Lp Rosen... | Buy 10 Aug 2022 | $16,907,067 |
| Capital Management Lp Rosen... | Buy 10 Aug 2022 | $40,401 |
| Target N Vbb Biotech Ag Bio... | Buy 18 May 2022 | $2,661,480 |
| Target N Vbb Biotech Ag Bio... | Buy 5 Jan 2022 | $3,470,500 |
| Capital Management Lp Rosen... | Buy 16 Dec 2021 | $1,037,063 |
| Capital Management Lp Rosen... | Buy 13 Dec 2021 | $3,189,442 |
Powered by
Robintrack.
Price target
Current $15.52
Average $20.25
Low $14
High $25
Dividends
| Ex-dividend date | N/A | Frequency | Irregular | Annual dividend | -0.07% |
|---|---|---|---|---|---|
| Next dividend | N/A | Dividend yield | 4.89% | Growth period | N/A |
| Last dividend date | Yield 3 years | 4.95% | Growth 3 years | -0.02% | |
| Last dividend | Yield 5 years | 5.98% | Growth 5 years | -0.01% |
| Insider | Age | Since | Compensation |
|---|---|---|---|
| Charles Morris (55) Chief Medical Officer since 2018 | 55 | 2018 | $1,660,660 |
| Chhaya Shah (57) Sr. VP and Chief Bus. Officer | 57 | $631,616 | |
| G. Kelly Martin (62) CEO, Pres, and Director | 62 | $612,367 | |
| Salvador Grausso III (46) Sr. VP and Head of U.S. Patient access | 46 | $530,421 | |
| Danielle Holtschlag (43) VP of Sales and Head of U.S. Sales Channels | 43 | $299,296 | |
| Owen Hughes (45) Independent Chairman of the board since 2020 | 45 | 2020 | $292,906 |
| Elhan Webb | 2019 | ||
| Sean Murphy | 2020 | ||
| Chhaya Shah | 2018 | ||
| Dan Dolan (44) Principal Financial Officer, Principal Accounting Officer, and Treasurer since 2020 | 44 | 2020 | |
| G. Kelly Martin (61) President, Chief Executive Officer, and Director since 2020 | 61 | 2020 | |
| Peter A. Schwartzman | |||
| Mark William Conley CPA (59) VP, CFO, Principal Accounting Officer, and Treasurer | 59 | ||
| Averi Price | |||
| Ethan Holdaway | |||
| Steven Helwig (48) Principal Fin., Accounting Officer, and Interim Treasurer | 48 | ||
| Dr. John A. Katzenellenbogen | |||
| Dr. Michael Rosenblatt M.D. (73) Founder, Board Observer, and Member of Scientific Advisory Board | 73 | ||
| Dr. John Thomas Potts Jr., DSc, M.D. (89) Founder and Member of the Scientific Advisory Board | 89 | ||
| Dr. Stavros C. Manolagas |
founded in 1906 as a one-man scrap metal operation, schnitzer steel industries, inc., has become one of the nation's largest recyclers of scrap metal, a leading provider of used and recycled auto parts and a manufacturer of finished steel products. with a rapidly growing national and global reach, the company achieved $2.5 billion in revenues in fiscal 2014 and was ranked #853 in the 2015 fortune 1000 list of companies. schnitzer steel common stock is traded on the nasdaq stock market under the symbol schn. with corporate headquarters based in portland, oregon, the company is split into three vertically integrated business units, the metals recycling business, the auto parts business and the steel manufacturing business. career site: http://www.schnitzersteel.com/careers.aspx
- Health Care > Pharmaceuticals
- Radius Recycling Inc., 22 Boston Wharf Road, Boston 02210, United States
- 617 551 4000
- Investor relations
Dividends
| Ex-dividend date | N/A | Frequency | Irregular | Annual dividend | -0.07% |
|---|---|---|---|---|---|
| Next dividend | N/A | Dividend yield | 4.89% | Growth period | N/A |
| Last dividend date | Yield 3 years | 4.95% | Growth 3 years | -0.02% | |
| Last dividend | Yield 5 years | 5.98% | Growth 5 years | -0.01% |
Quarterly EPS estimates
Profit margin
Debt to assets
Cash flow
Balance sheet
XSLX
| (in millions USD) | 31 Mar 2024 | 31 Dec 2023 | |||
|---|---|---|---|---|---|
| Current assets | |||||
| Cash | $13.562 | $4.408 | |||
| Short term investments | |||||
| Net receivables | $218.745 | $191.415 | |||
| Inventory | $314.421 | $281.062 | |||
| Total current assets | $594.592 | $535.447 | |||
| Long term investments | $10.491 | $10.268 | |||
| Property, plant & equipment | $809.664 | $813.68 | |||
| Goodwill & intangible assets | $260.598 | $262.065 | |||
| Total noncurrent assets | $1,150.937 | $1,157.207 | |||
| Total investments | $10.491 | $10.268 | |||
| Total assets | $1,745.529 | $1,692.654 | |||
| Current liabilities | |||||
| Accounts payable | $192.2 | $200.569 | |||
| Deferred revenue | |||||
| Short long term debt | $25.391 | $25.564 | |||
| Total current liabilities | $303.976 | $305.159 | |||
| Long term debt | $466.078 | $373.547 | |||
| Total noncurrent liabilities | $594.087 | $503.219 | |||
| Total debt | $491.469 | $399.111 | |||
| Total liabilities | $898.063 | $808.378 | |||
| Stockholders' equity | |||||
| Retained earnings | $831.636 | $870.975 | |||
| Other stockholder equity | -$39.684 | -$40.102 | |||
| Total stockholder equity | $844.437 | $880.994 | |||
| (in millions USD) | 2023 | 2022 | ||
|---|---|---|---|---|
| Current assets | ||||
| Cash | $6.032 | $43.803 | ||
| Short term investments | ||||
| Net receivables | $210.442 | $237.654 | ||
| Inventory | $278.642 | $315.189 | ||
| Total current assets | $550.34 | $671.386 | ||
| Long term investments | $10.75 | $12.841 | ||
| Property, plant & equipment | $822.491 | $786.533 | ||
| Goodwill & intangible assets | $261.959 | $281.353 | ||
| Total noncurrent assets | $1,165.609 | $1,155.211 | ||
| Total investments | $10.75 | $12.841 | ||
| Total assets | $1,715.949 | $1,826.597 | ||
| Current liabilities | ||||
| Accounts payable | $209.423 | $217.689 | ||
| Deferred revenue | ||||
| Short long term debt | $25.648 | $27.701 | ||
| Total current liabilities | $323.93 | $381.573 | ||
| Long term debt | $339.665 | $344.172 | ||
| Total noncurrent liabilities | $480.36 | $486.55 | ||
| Total debt | $365.313 | $371.873 | ||
| Total liabilities | $804.29 | $868.123 | ||
| Stockholders' equity | ||||
| Retained earnings | $894.316 | $941.146 | ||
| Other stockholder equity | -$39.683 | -$37.089 | ||
| Total stockholder equity | $908.18 | $953.979 | ||
Income statement
| (in millions USD) | 31 Mar 2024 | 31 Dec 2023 | |||
|---|---|---|---|---|---|
| Revenue | |||||
| Total revenue | $621.059 | $672.897 | |||
| Cost of revenue | $580.996 | $633.42 | |||
| Gross profit | $40.063 | $39.477 | |||
| Operating activities | |||||
| Research & development | |||||
| Selling, general & administrative | $62.16 | $63.102 | |||
| Total operating expenses | $67.074 | $63.307 | |||
| Operating income | -$27.011 | -$23.83 | |||
| Income from continuing operations | |||||
| EBIT | -$26.981 | -$23.324 | |||
| Income tax expense | $1.195 | -$10.17 | |||
| Interest expense | $5.803 | $4.81 | |||
| Net income | |||||
| Net income | -$33.979 | -$17.964 | |||
| Income (for common shares) | -$33.979 | -$17.964 | |||
| (in millions USD) | 2023 | 2022 | ||
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $2,882.224 | $3,485.815 | ||
| Cost of revenue | $2,574.513 | $2,997.745 | ||
| Gross profit | $307.711 | $488.07 | ||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | $265.929 | $263.257 | ||
| Total operating expenses | $319.288 | $265.596 | ||
| Operating income | -$11.577 | $222.474 | ||
| Income from continuing operations | ||||
| EBIT | -$9.949 | $221.935 | ||
| Income tax expense | -$2.747 | $44.597 | ||
| Interest expense | $18.589 | $8.538 | ||
| Net income | ||||
| Net income | -$25.791 | $168.8 | ||
| Income (for common shares) | -$25.791 | $168.8 | ||
Cash flows
| (in millions USD) | 31 Mar 2024 | 31 Dec 2023 | |||
|---|---|---|---|---|---|
| Net income | -$33.979 | -$17.964 | |||
| Operating activities | |||||
| Depreciation | $24.311 | $23.471 | |||
| Business acquisitions & disposals | |||||
| Stock-based compensation | $2.365 | $1.376 | |||
| Total cash flows from operations | -$55.094 | -$1.299 | |||
| Investing activities | |||||
| Capital expenditures | -$14.983 | -$24.808 | |||
| Investments | -$6 | ||||
| Total cash flows from investing | -$19.459 | -$24.199 | |||
| Financing activities | |||||
| Dividends paid | -$5.247 | -$5.551 | |||
| Sale and purchase of stock | |||||
| Net borrowings | $89.251 | $34.531 | |||
| Total cash flows from financing | $83.78 | $23.816 | |||
| Effect of exchange rate | -$0.073 | $0.058 | |||
| Change in cash and equivalents | $9.154 | -$1.624 | |||
| (in millions USD) | 2023 | 2022 | ||
|---|---|---|---|---|
| Net income | -$25.791 | $168.8 | ||
| Operating activities | ||||
| Depreciation | $89.76 | $75.053 | ||
| Business acquisitions & disposals | -$26.902 | -$179.721 | ||
| Stock-based compensation | $11.186 | $18.517 | ||
| Total cash flows from operations | $139.362 | $237.676 | ||
| Investing activities | ||||
| Capital expenditures | -$129.516 | -$150.201 | ||
| Investments | -$5 | |||
| Total cash flows from investing | -$143.969 | -$316.146 | ||
| Financing activities | ||||
| Dividends paid | -$21.186 | -$21.291 | ||
| Sale and purchase of stock | -$34.248 | |||
| Net borrowings | -$2.948 | $163.886 | ||
| Total cash flows from financing | -$33.132 | $94.574 | ||
| Effect of exchange rate | -$0.032 | -$0.119 | ||
| Change in cash and equivalents | -$37.771 | $15.985 | ||
Recent institutional transactions
| Quarter | Shareholder | Change |
Shares owned
Shares
|
Value (in thousands USD) |
|---|---|---|---|---|
| 2024 Q1 | Ameriprise Financial Inc |
-26.35%
|
1,206,384 | $25,490,894 |
| 2024 Q1 | Fmr |
-21.76%
|
770,747 | $16,285,878 |
| 2024 Q1 | Franklin Resources Inc |
Opened
|
165,183 | $3,490,317 |
| 2024 Q1 | Marshall Wace, LL.P. |
-87.81%
|
20,868 | $440,941 |
| 2024 Q1 | Fil Ltd |
-18.86%
|
435,658 | $9,205,453 |
| 2024 Q1 | Prudential Financial Inc |
+52.85%
|
284,008 | $6,001,089 |
| 2024 Q1 | American Century Companies Inc |
+21.19%
|
548,555 | $11,590,967 |
| 2024 Q1 | Jpmorgan Chase & Co |
-36.21%
|
164,786 | $3,481,928 |
| 2024 Q1 | Deprince Race & Zollo Inc |
+78.76%
|
188,200 | $3,976,666 |
| 2024 Q1 | Blackrock |
+2.43%
|
3,419,983 | $72,264,248 |
Institutional shareholders
| Shareholder | Stake |
Shares owned
Shares
|
Value (in thousands USD) |
|---|---|---|---|
| Bb Biotech Ag | 24.41% | 6,781,685 | |
| Blackrock | 12.31% | 3,419,983 | |
| Dimensional Fund Advisors L.P. | 7.91% | 2,198,145 | |
| Ameriprise Financial Inc | 4.34% | 1,206,384 | |
| State Street Corp | 3.98% | 1,106,946 | |
| Fmr | 2.77% | 770,747 | |
| Tang Capital Management | 2.75% | 763,888 | |
| D. E. Shaw & Co | 2.65% | 737,069 | |
| Bank Of New York Mellon Corp | 2.37% | 659,153 | |
| American Century Companies Inc | 1.97% | 548,555 |
Sign up